Barinthus Bio names Leon Hooftman as new CMO

UK clinical-stage biotech Barinthus Biotherapeutics (Nasdaq: BRNS), formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO).

“We are happy to welcome Dr Hooftman to Barinthus Bio as our chief medical officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth,” said chief executive Bill Enright, DDING: “Dr Hooftman’s background as a clinician and biotech CMO will be invaluable as we advance Barinthus Bio’s extensive pipeline and goals to develop first-in-class therapies for diseases with unmet needs.”

Dr Hooftman brings significant drug development expertise across a broad array of therapeutic areas including oncology, infectious diseases, and inflammation. His R&D portfolio includes successful clinical trial programs that resulted in the development of novel agents: mycophenolate mofetil (transplantation), rituximab (non-Hodgkin’s lymphoma), gemtuzumab ozogamycin (leukemia), and lipid complex amphotericin B (serious fungal infections).